<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054010</url>
  </required_header>
  <id_info>
    <org_study_id>TET-21-001</org_study_id>
    <nct_id>NCT05054010</nct_id>
  </id_info>
  <brief_title>Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants</brief_title>
  <official_title>Identification and Characterization of Commercial RUO Antibodies for the Detection of Specific Breast Cancer Tumoral Markers Expressed in Potential Circulating Tumoral Cells (CTCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tethis S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tethis S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory research study with the aim of identifying specific cancer biomarkers&#xD;
      in various subtypes of breast cancer. Blood samples will be collected from 60 participants&#xD;
      divided into 40 patients and 20 healthy donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this research study different commercial RUO (Research Use Only) antibodies will be&#xD;
      purchased and then tested on blood samples obtained by participants affected by breast cancer&#xD;
      and by healthy participants as control. Sixty participants will be enrolled belonging to&#xD;
      different categories: 20 participants affected by early breast cancer, 20 participants&#xD;
      affected by metastatic breast cancer, and 20 healthy volunteers to be used as negative&#xD;
      control.&#xD;
&#xD;
      After signing the informed consent form, participants will be screened to evaluate if they&#xD;
      meet the eligibility criteria. If all the criteria are met, participants will be enrolled&#xD;
      into the study and will be asked to provide some demographic and other data. A 13 ml blood&#xD;
      sample will be collected by the subjects and shipped to Tethis laboratories in order to be&#xD;
      processed and analysed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of commercial Antibodies capable of Identify specific Breast Cancer Biomarkers</measure>
    <time_frame>1 day (at the blood draw)</time_frame>
    <description>Qualitative Assessment of Staining Positivity for different Breast Cancer Biomarkers</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Early Breast Cancer patients</arm_group_label>
    <description>Early stage breast cancer category is based on the definition of the European Society of medical Oncology and is defined as disease confined to the breast with or without regional lymph node involvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer patients</arm_group_label>
    <description>Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <description>Participants who are in good health and without history of cancer disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected from among the people who visit the Breast Surgery department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give and sign a written informed consent for&#xD;
             participation in the study.&#xD;
&#xD;
          -  Female aged 18 years or above.&#xD;
&#xD;
          -  Diagnosed with early breast cancer (stage I and II) or metastatic breast cancer.&#xD;
&#xD;
          -  Healthy participants who visit the site for reason other than cancer diagnosis&#xD;
             (including breast cancer).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancies other than breast cancer (for healthy participants&#xD;
             includes also breast cancer).&#xD;
&#xD;
          -  Undergone surgery or treatment for breast cancer before enrollment (only for early&#xD;
             breast cancer).&#xD;
&#xD;
          -  Presence of known severe coagulation or haematological disorder&#xD;
&#xD;
          -  Known Pregnancy&#xD;
&#xD;
          -  Absence of written signed informed consent for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oreste Gentilini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oreste Gentilini, MD</last_name>
    <phone>+390226433939</phone>
    <email>chirurgia.mammella@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oreste D Gentilini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hench IB, Hench J, Tolnay M. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front Med (Lausanne). 2018 Jan 30;5:9. doi: 10.3389/fmed.2018.00009. eCollection 2018. Review.</citation>
    <PMID>29441349</PMID>
  </reference>
  <reference>
    <citation>Rawal S, Yang YP, Cote R, Agarwal A. Identification and Quantitation of Circulating Tumor Cells. Annu Rev Anal Chem (Palo Alto Calif). 2017 Jun 12;10(1):321-343. doi: 10.1146/annurev-anchem-061516-045405. Epub 2017 Mar 6. Review.</citation>
    <PMID>28301753</PMID>
  </reference>
  <reference>
    <citation>Carbone R, Marangi I, Zanardi A, Giorgetti L, Chierici E, Berlanda G, Podest√† A, Fiorentini F, Bongiorno G, Piseri P, Pelicci PG, Milani P. Biocompatibility of cluster-assembled nanostructured TiO2 with primary and cancer cells. Biomaterials. 2006 Jun;27(17):3221-9. Epub 2006 Feb 28.</citation>
    <PMID>16504283</PMID>
  </reference>
  <reference>
    <citation>Zanardi A, Bandiera D, Bertolini F, Corsini CA, Gregato G, Milani P, Barborini E, Carbone R. Miniaturized FISH for screening of onco-hematological malignancies. Biotechniques. 2010 Jul;49(1):497-504. doi: 10.2144/000113445.</citation>
    <PMID>20615202</PMID>
  </reference>
  <reference>
    <citation>Krol I, Schwab FD, Carbone R, Ritter M, Picocci S, De Marni ML, Stepien G, Franchi GM, Zanardi A, Rissoglio MD, Covelli A, Guidi G, Scarinci D, Castro-Giner F, Mazzarella L, Doglioni C, Borghi F, Milani P, Kurzeder C, Weber WP, Aceto N. Detection of clustered circulating tumour cells in early breast cancer. Br J Cancer. 2021 Jul;125(1):23-27. doi: 10.1038/s41416-021-01327-8. Epub 2021 Mar 24.</citation>
    <PMID>33762721</PMID>
  </reference>
  <reference>
    <citation>Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.</citation>
    <PMID>29453314</PMID>
  </reference>
  <reference>
    <citation>Xu L, Jia S, Li H, Yu Y, Liu G, Wu Y, Liu X, Liu C, Zhou Y, Zhang Z, Sheng Y. Characterization of circulating tumor cells in newly diagnosed breast cancer. Oncol Lett. 2018 Feb;15(2):2522-2528. doi: 10.3892/ol.2017.7540. Epub 2017 Dec 6.</citation>
    <PMID>29434968</PMID>
  </reference>
  <reference>
    <citation>Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017 Sep 28;12(9):e0185231. doi: 10.1371/journal.pone.0185231. eCollection 2017.</citation>
    <PMID>28957377</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer Biomarker</keyword>
  <keyword>Circulating Tumoral Cell</keyword>
  <keyword>Immunofluorescence Assay</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a basic research study without an IPD information sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

